In a report released on November 10, David Lebovitz from Citi maintained a Hold rating on 23andMe Holding (ME – Research Report). The company’s shares closed last Friday at $0.73.
Lebovitz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, PTC Therapeutics, and BioMarin Pharmaceutical. According to TipRanks, Lebovitz has an average return of -1.2% and a 47.57% success rate on recommended stocks.
23andMe Holding has an analyst consensus of Moderate Buy, with a price target consensus of $1.95.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $3.48 and a one-year low of $0.61. Currently, 23andMe Holding has an average volume of 3.27M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
23andMe Holding (ME) Company Description:
VG Acquisition Corp is a blank check company.
Read More on ME:
- 23andMe price target lowered to $3 from $5 at TD Cowen
- 23andMe launches Total Health, a new health membership
- 23andMe reports updated safety, preliminary efficacy data from Phase 1/2a study
- 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1
- 23andMe launches Health Action Plan to provide personalized recommendations
